Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
ACRS
#2714
Aclaris Therapeutics, Inc.
2.8
7
-8.01%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
-8.01%
Monthly Change
-26.41%
6 month change
+56.83%
Year Change
+50.26%
Previous Close
3.1
2
Open
2.8
7
Bid
Ask
Low
2.8
7
High
2.8
7
Volume
58
Markets
US Stock Market
Healthcare
ACRS
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
51.8 M
61.28 M
66.69 M
70.93 M
107.92 M
120.6 M
—
Valuation ratios
Enterprise value
313.11 M
863.59 M
959.79 M
34.59 M
243.07 M
343.03 M
787.37 M
Price to earnings ratio
—
-9.09
-11.33
-0.83
-1.45
-5.68
-8.75
Price to sales ratio
—
122
33.03
2.35
10.24
—
—
Price to cash flow ratio
—
15.82
14.55
0.94
9.55
7.83
-295.07
Price to book ratio
—
4.18
4.97
0.47
1.23
3.58
4.4
Enterprise value to EBITDA ratio
-17.26
-43.24
728.21
-2.55
-29.76
—
—
Profitability ratios
Return on assets %
0.72
0.36
0.34
0.45
0.6
0.4
0.36
Return on equity %
1.35
0.46
0.44
0.56
0.85
0.63
0.54
Return on invested capital %
1 118.27
1 086.25
958.37
798.73
657.83
210.26
190.61
Gross margin %
20.81
30.29
86.48
89.05
85.09
73.28
278.85
Operating margin %
785.44
1 327.07
302.01
311.55
758.18
975.91
4 554.14
EBITDA margin %
-279.93
-295.39
4.43
-43.39
-43.63
-201.67
-997.97
Net margin %
787.03
1 343.96
292.11
283.15
705.48
829.58
3 876.59
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
3.87
8.94
10.55
4.16
3.99
3.36
16.23
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.08
0.04
0.12
0.14
0.09
0.04
0.04
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
0.15
0.04
—
—
—
—
—
Long term debt to total equity ratio
0.28
0.05
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
0.92
1.04
1.12
0.26
0.38
0.38
EBIT per share
—
-0.37
0.01
-0.21
-0.12
-0.13
-0.13
EBITDA per share
—
-0.35
0.02
-0.19
-0.11
-0.13
-0.13
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
3.98
3.52
2.61
2.64
1.24
5.63
Net current asset value per share
—
3.61
3.55
1.85
1.63
0.79
3.35
Tangible book value per share
—
3.35
2.92
2.25
2.01
0.84
4.07
Working capital per share
—
3.21
3.21
1.4
1.22
0.55
2.51
Book value per share
—
3.48
3.03
2.25
2.01
0.84
4.07
News
Stifel raises Aclaris Therapeutics stock price target to $3 on pipeline
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Lags Revenue Estimates
Aclaris Therapeutics Inc earnings missed by $0.01, revenue fell short of estimates
Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates
Corcept Therapeutics (CORT) Q4 Earnings and Revenues Miss Estimates
Aclaris starts phase 1b trial of ATI-052 in asthma patients
Craig-Hallum initiates coverage on Aclaris Therapeutics stock with Buy rating
Aclaris stock gets Buy rating reaffirmed by H.C. Wainwright after positive preclinical results
Aclaris Hair Loss Drug Shows Faster Results Than Pfizer's Drug - Aclaris Therapeutics (NASDAQ:ACRS)
Aclaris reports positive preclinical results for hair loss drug
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.76%
Aclaris begins phase 1b trial of ATI-052 for atopic dermatitis